Tempus Reports Second Quarter 2025 Results
-
Revenue increased
89.6% year-over-year to$314.6 million -
Genomics revenue increased
115.3% year-over-year to$241.8 million 26% ) and Hereditary (32% ) testing -
Data and services revenue increased
35.7% year-over-year to$72.8 million 40.7% year-over-year -
Quarterly gross profit was
$195.0 million 158.3% year-over-year increase -
Issued
$750 million 0.75% convertible senior notes that will drive significant interest expense and cash savings -
Increasing full year 2025 revenue guidance to
$1.26 billion $5 million $110 million
“The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis,” said Eric Lefkofsky, Founder and CEO of Tempus. “We saw significant re-acceleration of our clinical volumes which grew
Second Quarter Summary Results
-
Quarterly revenue increased
89.6% year-over-year to$314.6 million -
Genomics contributed
$241.8 million 115.3% compared to the second quarter of 2024.-
Oncology testing (Tempus genomics) delivered
$133.2 million 32.9% year-over-year with approximately26% volume growth versus20% last quarter. -
Hereditary testing (Ambry genetics) contributed
$97.3 million 33.6% year-over-year on a pro forma basis1 with approximately32% volume growth.
-
Oncology testing (Tempus genomics) delivered
-
Revenue from Data and services totaled
$72.8 million 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), which grew40.7% year-over-year. -
Generated
$195.0 million 158.3% increase year-over-year. -
Improvement in reported net loss of (
$42.8 million $37.8 million ( , compared to a net loss of ($24.3) million $552.2 million -
Adjusted EBITDA of (
$5.6 million $31.2 million $25.6 million
1 |
The pro forma amounts have been calculated after applying the Company's accounting policies |
Second Quarter and Recent Operational Highlights
-
Strengthened Financial Flexibility: Just after quarter end, we completed an upsized offering of
$750 million 0.75% convertible senior notes, enhancing our balance sheet and allowing us to replace a portion of the existing term loan with a significantly lower interest debt instrument. We also ended the quarter with$293.0 million ~ over last quarter.$70 million - Expanded AI-Powered Clinical Tools: Extended Tempus Next™ care pathway intelligence platform into breast cancer, furthering AI-driven decision support across oncology. In addition, Tempus One™, our generative AI clinical assistant, was integrated into leading electronic health record (EHR) systems to enhance physician workflows and point-of-care insights.
- Advanced MRD and monitoring: Introduced Tempus xM™ for treatment and response monitoring (TRM), a liquid biopsy assay designed to monitor immunotherapy response in patients with advanced solid tumors, providing clinicians with actionable, real-time insights. We also expanded our exclusive collaboration with Personalis to include colorectal cancer as the fourth indication under the NeXT Personal® MRD commercial partnership.
- Reached new database milestone: Through more than 4,500 integrations, we are now connected to more than 40 million clinical patient records, with ~9 million de-identified and ingested, spanning ~1.1 billion healthcare documents, a significant percentage of which are connected to the ~4 million samples we have sequenced. As a result, our database now stands at >350 petabytes of connected clinical and molecular data.
- Approaching 10-Year anniversary: As we near Tempus’ 10-year anniversary, we’re reflecting on a decade of innovation and collaboration which now spans more than 2,000 publications including ~700 peer reviewed articles and ~180 oral presentations.
Second Quarter Financial Results |
||||||||||||
|
||||||||||||
|
|
Three Months Ended June 30, |
|
|
|
|
||||||
|
|
2025 |
|
|
2024 |
|
|
Change |
|
|||
|
|
(in thousands, except percentages and per share amounts) |
|
|
|
|
||||||
|
|
(unaudited) |
|
|
|
|
||||||
Revenue |
|
$ |
314,635 |
|
|
$ |
165,969 |
|
|
|
89.6 |
% |
Gross profit |
|
$ |
195,039 |
|
|
$ |
75,513 |
|
|
|
158.3 |
% |
Loss from operations |
|
$ |
(61,774 |
) |
|
$ |
(533,492 |
) |
|
NM(1) |
|
|
Net loss |
|
$ |
(42,843 |
) |
|
$ |
(552,212 |
) |
|
NM(1) |
|
|
Adjusted EBITDA |
|
$ |
(5,580 |
) |
|
$ |
(31,186 |
) |
|
|
82.1 |
% |
Net loss per share attributable to common shareholders, basic and diluted |
|
$ |
(0.25 |
) |
|
$ |
(6.86 |
) |
|
|
96.4 |
% |
Non-GAAP net loss per share |
|
$ |
(0.22 |
) |
|
$ |
(0.63 |
) |
|
|
65.1 |
% |
| ____________ | |
(1) |
Not meaningful due to the impact of stock compensation expense and employer payroll tax related to stock-based compensation associated with the initial public offering in June 2024 |
Financial Outlook and Guidance
Tempus is increasing its guidance and now expects full year 2025 revenue of approximately
For additional information on the quarter, including a letter from our CEO and CFO, please visit our investors relations site at investors.tempus.com.
Webcast and Conference Call Information
A conference call and webcast will be held on Friday, August 8, 2025 at 8:00 a.m. Eastern Time. Interested parties may access details using:
Conference ID: 7005219
Domestic Dial-in Number: (800) 715 - 9871
International Dial-in Number: (646) 307 - 1963
Live webcast: https://edge.media-server.com/mmc/p/irtvw27b
The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter and year by Eric Lefkofsky, Founder and CEO and Jim Rogers, CFO, which will be discussed on the conference call and webcast.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Non-GAAP Financial Measures
In addition to the financial information presented in this release in accordance with accounting principles generally accepted in
Non-GAAP gross profit is defined as GAAP gross profit, excluding stock-based compensation expense and employer payroll tax related to stock-based compensation (collectively, the “stock-based compensation adjustments”). Non-GAAP gross margin is defined as gross profit, excluding the stock-based compensation adjustments, as a percentage of revenue. Non-GAAP operating expenses are calculated as the sum of technology research and development expense, research and development expense, and selling, general and administrative expense, excluding the stock-based compensation adjustments, acquisition-related expenses, amortization of intangibles due to acquisition, and franchise taxes related to our IPO. Non-GAAP loss from operations is defined as loss from operations, adjusted to exclude (i) stock-based compensation expense, (ii) employer payroll tax related to stock-based compensation expense, (iii) acquisition-related expenses, (iv) franchise taxes related to our IPO, and (v) amortization of intangibles due to acquisition. Non-GAAP net loss is defined as net loss, adjusted to exclude (i) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (ii) stock-based compensation expense, (iii) employer payroll tax related to stock-based compensation expense, (iv) acquisition-related expenses, (v) amortization of intangibles due to acquisition, (vi) losses on equity method investments, (vii) (benefit from) provision for income taxes, (viii) the payment of
Adjusted EBITDA is defined as net loss, adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) provision for (benefit from) income taxes, (v) losses on equity method investments, (vi) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (vii) stock-based compensation expense, (viii) employer payroll tax related to stock-based compensation expense, (ix) acquisition related expenses, (x) the G-4 Special Payment, (xi) amortization of deferred other income from our IP License Agreement with SB Tempus, and (xii) franchise taxes related to our IPO.
Tempus believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.
Tempus does not provide guidance for net loss, the most directly comparable GAAP measure to EBITDA and Adjusted EBITDA, and similarly cannot provide a reconciliation between Tempus’ forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net income (loss) and the respective reconciliations. These forecasted items are not within Tempus’ control, may vary greatly between periods, and could significantly impact future financial results.
Other Key Metrics
Total Remaining Contract Value (TCV) is equal to the total potential value of signed contracts and assumes the exercise of all contract options, all discretionary opt-ins, and no early termination. Remaining TCV excludes any revenue recognized to date on these contracts or any future adjustments made to the contractual value as a result of amendments or terminations.
Net Revenue Retention compares the annual Insights product revenue generated from all customers that made an Insights purchase in one year to the annual Insights product revenue generated from the same cohort of customers in the subsequent year.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, Tempus’ expected financial results for full year 2025; expectations concerning the interest and cost savings associated with our convertible senior notes; and other statements that are not historical fact. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including Tempus’ ability to realize the expected benefits of the acquisition of Ambry Genetics and Deep 6 AI; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, trade tensions and tariffs, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“the SEC”) on February 24, 2025, as supplemented by Tempus' Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 8, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Tempus AI, Inc. |
||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
||||||||||||||||
(Unaudited) |
||||||||||||||||
(in thousands, except per share amounts) |
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Net revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Genomics |
|
$ |
241,843 |
|
|
$ |
112,324 |
|
|
$ |
435,647 |
|
|
$ |
214,893 |
|
Data and services(1) |
|
|
72,792 |
|
|
|
53,645 |
|
|
|
134,725 |
|
|
|
96,896 |
|
Total net revenue |
|
$ |
314,635 |
|
|
$ |
165,969 |
|
|
$ |
570,372 |
|
|
$ |
311,789 |
|
Cost and operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of revenues, genomics |
|
|
99,756 |
|
|
|
68,324 |
|
|
|
184,539 |
|
|
|
121,159 |
|
Cost of revenues, data and services |
|
|
19,840 |
|
|
|
22,132 |
|
|
|
35,591 |
|
|
|
37,420 |
|
Technology research and development |
|
|
34,482 |
|
|
|
77,908 |
|
|
|
67,873 |
|
|
|
104,975 |
|
Research and development |
|
|
41,619 |
|
|
|
68,025 |
|
|
|
77,493 |
|
|
|
92,365 |
|
Selling, general and administrative |
|
|
180,712 |
|
|
|
463,072 |
|
|
|
335,339 |
|
|
|
542,636 |
|
Total cost and operating expenses |
|
|
376,409 |
|
|
|
699,461 |
|
|
|
700,835 |
|
|
|
898,555 |
|
Loss from operations |
|
$ |
(61,774 |
) |
|
$ |
(533,492 |
) |
|
$ |
(130,463 |
) |
|
$ |
(586,766 |
) |
Interest income |
|
|
1,093 |
|
|
|
1,718 |
|
|
|
2,906 |
|
|
|
2,749 |
|
Interest expense |
|
|
(21,579 |
) |
|
|
(13,295 |
) |
|
|
(39,582 |
) |
|
|
(26,533 |
) |
Other income (expense), net |
|
|
41,729 |
|
|
|
(7,048 |
) |
|
|
14,274 |
|
|
|
(6,299 |
) |
Loss before (provision for) benefit from income taxes |
|
$ |
(40,531 |
) |
|
$ |
(552,117 |
) |
|
$ |
(152,865 |
) |
|
$ |
(616,849 |
) |
(Provision for) benefit from income taxes |
|
|
(212 |
) |
|
|
(95 |
) |
|
|
45,968 |
|
|
|
(106 |
) |
Losses from equity method investments |
|
|
(2,100 |
) |
|
|
— |
|
|
|
(3,983 |
) |
|
|
— |
|
Net Loss |
|
$ |
(42,843 |
) |
|
$ |
(552,212 |
) |
|
$ |
(110,880 |
) |
|
$ |
(616,955 |
) |
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares |
|
|
— |
|
|
|
(11,540 |
) |
|
|
— |
|
|
|
(39,347 |
) |
Cumulative undeclared dividends on Series C preferred shares |
|
|
— |
|
|
|
(668 |
) |
|
|
— |
|
|
|
(1,174 |
) |
Net loss attributable to common shareholders, basic and diluted |
|
|
(42,843 |
) |
|
|
(564,420 |
) |
|
|
(110,880 |
) |
|
|
(657,476 |
) |
Net loss per share attributable to common shareholders, basic and diluted |
|
$ |
(0.25 |
) |
|
$ |
(6.86 |
) |
|
$ |
(0.64 |
) |
|
$ |
(9.02 |
) |
Weighted-average shares outstanding used to compute net loss per share, basic and diluted |
|
|
173,381 |
|
|
|
82,325 |
|
|
|
171,960 |
|
|
|
72,930 |
|
Comprehensive Loss, net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
$ |
(42,843 |
) |
|
$ |
(552,212 |
) |
|
$ |
(110,880 |
) |
|
$ |
(616,955 |
) |
Foreign currency translation adjustment |
|
|
3,756 |
|
|
|
(43 |
) |
|
|
8,354 |
|
|
|
(99 |
) |
Comprehensive loss |
|
$ |
(39,087 |
) |
|
$ |
(552,255 |
) |
|
$ |
(102,526 |
) |
|
$ |
(617,054 |
) |
(1) |
Includes related party revenue of |
Tempus AI, Inc. |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(Unaudited) |
||||||||
(in thousands, except share and per share amounts) |
||||||||
|
||||||||
|
|
June 30, 2025 |
|
|
December 31, 2024 |
|
||
Assets |
|
|
|
|
|
|
||
Current Assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
186,310 |
|
|
$ |
340,954 |
|
Accounts receivable, net of allowances of |
|
|
266,284 |
|
|
|
154,819 |
|
Inventory |
|
|
47,600 |
|
|
|
38,386 |
|
Related party asset |
|
|
2,535 |
|
|
|
— |
|
Prepaid expenses and other current assets |
|
|
36,476 |
|
|
|
26,135 |
|
Marketable equity securities |
|
|
104,996 |
|
|
|
107,309 |
|
Total current assets |
|
$ |
644,201 |
|
|
$ |
667,603 |
|
Property and equipment, net |
|
|
92,563 |
|
|
|
58,056 |
|
Goodwill |
|
|
325,793 |
|
|
|
73,343 |
|
Intangible assets, net |
|
|
387,564 |
|
|
|
11,716 |
|
Investments and other assets |
|
|
16,669 |
|
|
|
8,305 |
|
Investment in joint venture |
|
|
95,718 |
|
|
|
91,450 |
|
Related party asset, less current portion |
|
|
22,465 |
|
|
|
— |
|
Operating lease right-of-use assets |
|
|
38,651 |
|
|
|
14,762 |
|
Restricted cash |
|
|
1,741 |
|
|
|
881 |
|
Total Assets |
|
$ |
1,625,365 |
|
|
$ |
926,116 |
|
|
|
|
|
|
|
|
||
Liabilities, Convertible redeemable preferred stock, and Stockholders' equity |
|
|
|
|
|
|
||
Current Liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
|
79,323 |
|
|
|
53,804 |
|
Related party payable |
|
|
25,000 |
|
|
|
— |
|
Accrued expenses |
|
|
165,903 |
|
|
|
130,407 |
|
Deferred revenue(1) |
|
|
100,477 |
|
|
|
75,981 |
|
Deferred other income |
|
|
15,955 |
|
|
|
15,955 |
|
Other current liabilities |
|
|
16,554 |
|
|
|
6,964 |
|
Operating lease liabilities |
|
|
9,381 |
|
|
|
6,459 |
|
Accrued data licensing fees |
|
|
5,567 |
|
|
|
1,500 |
|
Total current liabilities |
|
$ |
418,160 |
|
|
$ |
291,070 |
|
Operating lease liabilities, less current portion |
|
|
45,866 |
|
|
|
26,199 |
|
Convertible promissory note |
|
|
226,342 |
|
|
|
168,192 |
|
Other long-term liabilities |
|
|
9,508 |
|
|
|
15,980 |
|
Revolving credit facility |
|
|
100,000 |
|
|
|
— |
|
Interest payable |
|
|
5,084 |
|
|
|
70,450 |
|
Long-term debt, net |
|
|
471,663 |
|
|
|
267,244 |
|
Deferred other income, less current portion |
|
|
15,955 |
|
|
|
23,932 |
|
Deferred revenue, less current portion |
|
|
23,225 |
|
|
|
6,710 |
|
Total Liabilities |
|
$ |
1,315,803 |
|
|
$ |
869,777 |
|
(1) |
Includes related party deferred revenue of |
Commitments and contingencies (Note 8) |
|
|
|
|
|
|
||
Convertible redeemable preferred stock, |
|
$ |
— |
|
|
$ |
— |
|
Stockholders' equity |
|
|
|
|
|
|
||
Class A Voting Common Stock, |
|
|
17 |
|
|
|
16 |
|
Class B Voting Common Stock, |
|
|
1 |
|
|
|
1 |
|
Non-voting Common Stock, |
|
|
— |
|
|
|
— |
|
Treasury Stock, 145,466 shares at June 30, 2025 and December 31, 2024, at cost |
|
|
(3,602 |
) |
|
|
(3,602 |
) |
Additional Paid-In Capital |
|
|
2,566,412 |
|
|
|
2,210,664 |
|
Accumulated Other Comprehensive Income |
|
|
8,448 |
|
|
|
94 |
|
Accumulated deficit |
|
|
(2,261,714 |
) |
|
|
(2,150,834 |
) |
Total Stockholders' equity |
|
$ |
309,562 |
|
|
$ |
56,339 |
|
Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity |
|
$ |
1,625,365 |
|
|
$ |
926,116 |
|
Tempus AI, Inc. |
|||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||
(Unaudited) |
|||||||
(in thousands, except per share amounts) |
|||||||
|
|||||||
|
Six Months Ended
|
|
|||||
|
2025 |
|
|
2024 |
|
||
Operating activities |
|
|
|
|
|
||
Net loss |
$ |
(110,880 |
) |
|
$ |
(616,955 |
) |
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
|
|
|
||
Change in fair value of warrant liability |
$ |
— |
|
|
$ |
(900 |
) |
Stock-based compensation |
|
45,429 |
|
|
|
488,313 |
|
Gain on warrant exercise |
|
— |
|
|
|
(173 |
) |
Gain on marketable equity securities |
|
(6,007 |
) |
|
|
(2,541 |
) |
Deferred income taxes |
|
(46,216 |
) |
|
|
— |
|
Losses from equity method investments |
|
3,983 |
|
|
|
— |
|
Amortization of original issue discount |
|
1,169 |
|
|
|
691 |
|
Amortization of deferred financing fees |
|
332 |
|
|
|
255 |
|
Change in fair value of contingent consideration |
|
— |
|
|
|
165 |
|
Change in fair value of holdback liability |
|
312 |
|
|
|
— |
|
Amortization of warrant contract asset |
|
— |
|
|
|
2,422 |
|
Depreciation and amortization |
|
48,385 |
|
|
|
18,348 |
|
Provision for bad debt expense |
|
625 |
|
|
|
327 |
|
Change in fair value of warrant asset |
|
— |
|
|
|
7,700 |
|
Non-cash operating lease costs |
|
4,573 |
|
|
|
3,252 |
|
Minimum accretion expense |
|
108 |
|
|
|
92 |
|
PIK interest added to principal |
|
7,157 |
|
|
|
4,366 |
|
Change in assets and liabilities |
|
|
|
|
|
||
Accounts receivable |
|
(49,155 |
) |
|
|
(23,971 |
) |
Inventory |
|
1,974 |
|
|
|
(3,845 |
) |
Prepaid expenses and other current assets |
|
(188 |
) |
|
|
(12,409 |
) |
Investments and other assets |
|
(11,073 |
) |
|
|
1,294 |
|
Accounts payable |
|
7,025 |
|
|
|
(33,371 |
) |
Deferred revenue(1) |
|
36,836 |
|
|
|
(28,669 |
) |
Deferred other income |
|
(7,977 |
) |
|
|
— |
|
Accrued data licensing fees |
|
3,957 |
|
|
|
(2,749 |
) |
Accrued expenses & other |
|
6,991 |
|
|
|
(2,805 |
) |
Interest payable |
|
7,122 |
|
|
|
7,287 |
|
Operating lease liabilities |
|
(5,942 |
) |
|
|
(4,582 |
) |
Net cash used in operating activities |
$ |
(61,460 |
) |
|
$ |
(198,458 |
) |
|
|
|
|
|
|
||
Investing activities |
|
|
|
|
|
||
Purchases of property and equipment |
$ |
(9,588 |
) |
|
$ |
(14,116 |
) |
Proceeds from sale of marketable equity securities |
|
8,316 |
|
|
|
23,098 |
|
Business combinations, net of cash acquired (Note 4) |
|
(380,762 |
) |
|
|
— |
|
Purchases of capitalized software |
|
(3,295 |
) |
|
|
— |
|
Net cash (used in) provided by investing activities |
$ |
(385,329 |
) |
|
$ |
8,982 |
|
(1) |
Includes increase in related party deferred revenue of |
Financing activities |
|
|
|
|
|
||
Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions |
$ |
— |
|
|
$ |
381,951 |
|
Tax withholding related to net share settlement of restricted stock units |
|
— |
|
|
|
(69,918 |
) |
Issuance of Series G-5 Preferred Stock |
|
— |
|
|
|
199,750 |
|
Payment of deferred offering costs |
|
— |
|
|
|
(2,714 |
) |
Dividends paid |
|
— |
|
|
|
(5,625 |
) |
Proceeds from revolving credit facility, net of original issue discount |
|
98,000 |
|
|
|
— |
|
Proceeds from long-term debt, net of original issue discount |
|
196,000 |
|
|
|
— |
|
Payment of deferred financing fees |
|
(958 |
) |
|
|
— |
|
Payment of indemnity holdback related to acquisition |
|
— |
|
|
|
(813 |
) |
Net cash provided by financing activities |
$ |
293,042 |
|
|
$ |
502,631 |
|
Effect of foreign exchange rates on cash |
$ |
(37 |
) |
|
$ |
(90 |
) |
|
|
|
|
|
|
||
Net (decrease) increase in Cash, Cash Equivalents and Restricted Cash |
$ |
(153,784 |
) |
|
$ |
313,065 |
|
Cash, cash equivalents and restricted cash, beginning of period |
|
341,835 |
|
|
|
166,607 |
|
Cash, cash equivalents and restricted cash, end of period |
$ |
188,051 |
|
|
$ |
479,672 |
|
|
|
|
|
|
|
||
Cash, Cash Equivalents and Restricted Cash are Comprised of: |
|
|
|
|
|
||
Cash and cash equivalents |
$ |
186,310 |
|
|
$ |
478,811 |
|
Restricted cash and cash equivalents |
|
1,741 |
|
|
|
861 |
|
Total cash, cash equivalents and restricted cash |
$ |
188,051 |
|
|
$ |
479,672 |
|
|
|
|
|
|
|
||
Supplemental disclosure of cash flow information |
|
|
|
|
|
||
Cash paid during the year for interest |
$ |
23,980 |
|
|
$ |
13,921 |
|
Cash paid for income taxes |
$ |
136 |
|
|
$ |
89 |
|
|
|
|
|
|
|
||
Supplemental disclosure of noncash investing and financing activities |
|
|
|
|
|
||
Dividends payable |
$ |
— |
|
|
$ |
5,487 |
|
Purchases of property and equipment, accrued but not paid |
$ |
6,863 |
|
|
$ |
1,108 |
|
Redemption of convertible promissory note |
$ |
14,338 |
|
|
$ |
12,476 |
|
Non-voting common stock issued in connection with business combinations |
$ |
— |
|
|
$ |
344 |
|
Deferred financing fees, accrued but not yet paid |
$ |
545 |
|
|
$ |
— |
|
Deferred offering costs, accrued but not yet paid |
$ |
95 |
|
|
$ |
6,051 |
|
Operating lease liabilities arising from obtaining right-of-use assets |
$ |
606 |
|
|
$ |
— |
|
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering |
$ |
— |
|
|
$ |
1,348,809 |
|
Taxes related to net share settlement of restricted stock units not yet paid |
$ |
— |
|
|
$ |
164 |
|
Reclassification of deferred offering costs to additional paid-in capital upon initial public offering |
$ |
— |
|
|
$ |
12,347 |
|
Class A Voting Common Stock issued in connection with business combinations |
$ |
310,320 |
|
|
$ |
— |
|
Issuance of Series G-3 Preferred Stock |
$ |
— |
|
|
$ |
3,809 |
|
Issuance of Series G-4 Preferred Stock |
$ |
— |
|
|
$ |
611 |
|
Convertible promissory note principal reset due to amendment |
$ |
72,488 |
|
|
$ |
— |
|
Tempus AI, Inc. |
||||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES |
||||||||||||||||
(Unaudited) |
||||||||||||||||
(in thousands, except percentages and per share amounts) |
||||||||||||||||
|
||||||||||||||||
Genomics Gross Profit & Gross Margin |
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Genomics revenue |
|
$ |
241,843 |
|
|
$ |
112,324 |
|
|
$ |
435,647 |
|
|
$ |
214,893 |
|
Cost of revenues, genomics |
|
|
99,756 |
|
|
|
68,324 |
|
|
|
184,539 |
|
|
|
121,159 |
|
Gross profit, genomics |
|
$ |
142,087 |
|
|
$ |
44,000 |
|
|
$ |
251,108 |
|
|
$ |
93,734 |
|
Stock-based compensation expense |
|
|
1,420 |
|
|
|
11,327 |
|
|
|
2,455 |
|
|
|
11,327 |
|
Employer payroll tax related to stock-based compensation |
|
|
254 |
|
|
|
136 |
|
|
|
302 |
|
|
|
136 |
|
Non-GAAP gross profit, genomics |
|
$ |
143,761 |
|
|
$ |
55,463 |
|
|
$ |
253,865 |
|
|
$ |
105,197 |
|
Genomics gross margin |
|
|
58.8 |
% |
|
|
39.2 |
% |
|
|
57.6 |
% |
|
|
43.6 |
% |
Stock-based compensation expense |
|
|
0.6 |
% |
|
|
10.1 |
% |
|
|
0.6 |
% |
|
|
5.3 |
% |
Employer payroll tax related to stock-based compensation |
|
|
0.1 |
% |
|
|
0.1 |
% |
|
|
0.1 |
% |
|
|
0.1 |
% |
Non-GAAP gross margin, genomics |
|
|
59.4 |
% |
|
|
49.4 |
% |
|
|
58.3 |
% |
|
|
49.0 |
% |
Data and Services Gross Profit & Gross Margin |
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Data and services revenue |
|
$ |
72,792 |
|
|
$ |
53,645 |
|
|
$ |
134,725 |
|
|
$ |
96,896 |
|
Cost of revenues, data and services |
|
|
19,840 |
|
|
|
22,132 |
|
|
|
35,591 |
|
|
|
37,420 |
|
Gross profit, data and services |
|
$ |
52,952 |
|
|
$ |
31,513 |
|
|
$ |
99,134 |
|
|
$ |
59,476 |
|
Stock-based compensation expense |
|
|
693 |
|
|
|
7,229 |
|
|
|
1,304 |
|
|
|
7,229 |
|
Employer payroll tax related to stock-based compensation |
|
|
114 |
|
|
|
119 |
|
|
|
158 |
|
|
|
119 |
|
Non-GAAP gross profit, data and services |
|
$ |
53,759 |
|
|
$ |
38,861 |
|
|
$ |
100,596 |
|
|
$ |
66,824 |
|
Gross margin, data and services |
|
|
72.7 |
% |
|
|
58.7 |
% |
|
|
73.6 |
% |
|
|
61.4 |
% |
Stock-based compensation expense |
|
|
1.0 |
% |
|
|
13.5 |
% |
|
|
1.0 |
% |
|
|
7.5 |
% |
Employer payroll tax related to stock-based compensation |
|
|
0.2 |
% |
|
|
0.2 |
% |
|
|
0.1 |
% |
|
|
0.1 |
% |
Non-GAAP gross margin, data and services |
|
|
73.9 |
% |
|
|
72.4 |
% |
|
|
74.7 |
% |
|
|
69.0 |
% |
Total Gross Profit & Gross Margin |
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Net revenue |
|
$ |
314,635 |
|
|
$ |
165,969 |
|
|
$ |
570,372 |
|
|
$ |
311,789 |
|
Cost of revenues |
|
|
119,596 |
|
|
|
90,456 |
|
|
|
220,130 |
|
|
|
158,579 |
|
Gross profit |
|
$ |
195,039 |
|
|
$ |
75,513 |
|
|
$ |
350,242 |
|
|
$ |
153,210 |
|
Stock-based compensation expense |
|
|
2,113 |
|
|
|
18,556 |
|
|
|
3,759 |
|
|
|
18,556 |
|
Employer payroll tax related to stock-based compensation |
|
|
369 |
|
|
|
255 |
|
|
|
460 |
|
|
|
255 |
|
Non-GAAP gross profit |
|
$ |
197,521 |
|
|
$ |
94,324 |
|
|
$ |
354,461 |
|
|
$ |
172,021 |
|
Gross margin |
|
|
62.0 |
% |
|
|
45.5 |
% |
|
|
61.4 |
% |
|
|
49.1 |
% |
Stock-based compensation expense |
|
|
0.7 |
% |
|
|
11.2 |
% |
|
|
0.7 |
% |
|
|
6.0 |
% |
Employer payroll tax related to stock-based compensation |
|
|
0.1 |
% |
|
|
0.2 |
% |
|
|
0.1 |
% |
|
|
0.1 |
% |
Non-GAAP gross margin |
|
|
62.8 |
% |
|
|
56.8 |
% |
|
|
62.1 |
% |
|
|
55.2 |
% |
Operating Expenses |
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Technology research and development |
|
$ |
34,482 |
|
|
$ |
77,908 |
|
|
$ |
67,873 |
|
|
$ |
104,975 |
|
Stock-based compensation expense |
|
|
3,285 |
|
|
|
50,434 |
|
|
|
6,604 |
|
|
|
50,434 |
|
Employer payroll tax related to stock-based compensation |
|
|
495 |
|
|
|
1,248 |
|
|
|
756 |
|
|
|
1,248 |
|
Non-GAAP technology research and development |
|
$ |
30,702 |
|
|
$ |
26,226 |
|
|
$ |
60,513 |
|
|
$ |
53,293 |
|
Research and development |
|
$ |
41,619 |
|
|
$ |
68,025 |
|
|
$ |
77,493 |
|
|
$ |
92,365 |
|
Stock-based compensation expense |
|
|
2,335 |
|
|
|
42,233 |
|
|
|
4,317 |
|
|
|
42,233 |
|
Employer payroll tax related to stock-based compensation |
|
|
235 |
|
|
|
676 |
|
|
|
411 |
|
|
|
676 |
|
Non-GAAP research and development |
|
$ |
39,049 |
|
|
$ |
25,116 |
|
|
$ |
72,765 |
|
|
$ |
49,456 |
|
Selling, general and administrative |
|
$ |
180,712 |
|
|
$ |
463,072 |
|
|
$ |
335,339 |
|
|
$ |
542,636 |
|
Stock-based compensation expense |
|
|
14,722 |
|
|
|
377,090 |
|
|
|
30,749 |
|
|
|
377,090 |
|
Employer payroll tax related to stock-based compensation |
|
|
774 |
|
|
|
2,582 |
|
|
|
5,499 |
|
|
|
2,582 |
|
Acquisition related expenses |
|
|
1,992 |
|
|
|
— |
|
|
|
5,521 |
|
|
|
— |
|
Amortization of intangibles due to acquisition |
|
|
16,771 |
|
|
|
— |
|
|
|
27,927 |
|
|
|
— |
|
| Franchise taxes related to IPO | 1,647 |
— |
1,647 |
— |
||||||||||||
Non-GAAP selling, general and administrative |
|
$ |
144,806 |
|
|
$ |
83,400 |
|
|
$ |
263,996 |
|
|
$ |
162,964 |
|
Operating expenses |
|
$ |
256,813 |
|
|
$ |
609,005 |
|
|
$ |
480,705 |
|
|
$ |
739,976 |
|
Stock-based compensation expense |
|
|
20,342 |
|
|
|
469,757 |
|
|
|
41,670 |
|
|
|
469,757 |
|
Employer payroll tax related to stock-based compensation |
|
|
1,504 |
|
|
|
4,506 |
|
|
|
6,666 |
|
|
|
4,506 |
|
Acquisition related expenses |
|
|
1,992 |
|
|
|
— |
|
|
|
5,521 |
|
|
|
— |
|
Amortization of intangibles due to acquisition |
|
|
16,771 |
|
|
|
— |
|
|
|
27,927 |
|
|
|
— |
|
| Franchise taxes related to IPO | 1,647 |
— |
1,647 |
— |
||||||||||||
Non-GAAP operating expenses |
|
$ |
214,557 |
|
|
$ |
134,742 |
|
|
$ |
397,274 |
|
|
$ |
265,713 |
|
Earnings per Share |
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Net loss |
|
$ |
(42,843 |
) |
|
$ |
(552,212 |
) |
|
$ |
(110,880 |
) |
|
$ |
(616,955 |
) |
Fair value changes(1) |
|
|
(37,546 |
) |
|
|
4,870 |
|
|
|
(5,696 |
) |
|
|
4,280 |
|
Stock-based compensation expense |
|
|
22,455 |
|
|
|
488,313 |
|
|
|
45,429 |
|
|
|
488,313 |
|
Employer payroll tax related to stock-based compensation |
|
|
1,873 |
|
|
|
4,762 |
|
|
|
7,126 |
|
|
|
4,762 |
|
Acquisition related expenses(2) |
|
|
1,992 |
|
|
|
— |
|
|
|
5,521 |
|
|
|
— |
|
Amortization of intangibles due to acquisition |
|
|
16,771 |
|
|
|
— |
|
|
|
27,927 |
|
|
|
— |
|
Losses on equity method investments |
|
|
2,100 |
|
|
|
— |
|
|
|
3,983 |
|
|
|
— |
|
Provision for (benefit from) income taxes |
|
|
212 |
|
|
|
95 |
|
|
|
(45,968 |
) |
|
|
106 |
|
G-4 Special Payment |
|
|
— |
|
|
|
2,250 |
|
|
|
— |
|
|
|
2,250 |
|
| Franchise taxes related to IPO | 1,647 |
— |
1,647 |
— |
||||||||||||
Amortization of technology license |
|
|
(3,988 |
) |
|
|
— |
|
|
|
(7,977 |
) |
|
|
— |
|
Non-GAAP net loss |
|
$ |
(37,327 |
) |
|
$ |
(51,922 |
) |
|
$ |
(78,888 |
) |
|
$ |
(117,244 |
) |
Non-GAAP net loss per share |
|
$ |
(0.22 |
) |
|
$ |
(0.63 |
) |
|
$ |
(0.46 |
) |
|
$ |
(1.61 |
) |
Weighted average common shares outstanding, basic and diluted |
|
|
173,381 |
|
|
|
82,325 |
|
|
|
171,960 |
|
|
|
72,930 |
|
(1) |
Fair value changes include gains and losses related to quarterly fair value adjustments of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities, and indemnity-related holdback liabilities. |
(2) |
Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and six months ended June 30, 2025. |
Adjusted EBITDA |
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Net loss |
|
$ |
(42,843 |
) |
|
$ |
(552,212 |
) |
|
$ |
(110,880 |
) |
|
$ |
(616,955 |
) |
Interest income |
|
|
(1,093 |
) |
|
|
(1,718 |
) |
|
|
(2,906 |
) |
|
|
(2,749 |
) |
Interest expense |
|
|
21,579 |
|
|
|
13,295 |
|
|
|
39,582 |
|
|
|
26,533 |
|
Depreciation |
|
|
8,347 |
|
|
|
6,415 |
|
|
|
16,230 |
|
|
|
12,684 |
|
Amortization |
|
|
19,685 |
|
|
|
2,744 |
|
|
|
32,155 |
|
|
|
5,664 |
|
Provision for (benefit from) income taxes |
|
|
212 |
|
|
|
95 |
|
|
|
(45,968 |
) |
|
|
106 |
|
EBITDA |
|
$ |
5,887 |
|
|
$ |
(531,381 |
) |
|
$ |
(71,787 |
) |
|
$ |
(574,717 |
) |
Losses on equity method investments |
|
|
2,100 |
|
|
|
— |
|
|
|
3,983 |
|
|
|
— |
|
Fair value changes(1) |
|
|
(37,546 |
) |
|
|
4,870 |
|
|
|
(5,696 |
) |
|
|
4,280 |
|
Stock-based compensation expense |
|
|
22,455 |
|
|
|
488,313 |
|
|
|
45,429 |
|
|
|
488,313 |
|
Employer payroll tax related to stock-based compensation |
|
|
1,873 |
|
|
|
4,762 |
|
|
|
7,126 |
|
|
|
4,762 |
|
Acquisition related expenses(2) |
|
|
1,992 |
|
|
|
— |
|
|
|
5,521 |
|
|
|
— |
|
G-4 Special Payment |
|
|
— |
|
|
|
2,250 |
|
|
|
— |
|
|
|
2,250 |
|
Amortization of technology license |
|
|
(3,988 |
) |
|
|
— |
|
|
|
(7,977 |
) |
|
|
— |
|
Franchise taxes related to IPO |
|
|
1,647 |
|
|
|
— |
|
|
|
1,647 |
|
|
|
— |
|
Adjusted EBITDA |
|
$ |
(5,580 |
) |
|
$ |
(31,186 |
) |
|
$ |
(21,754 |
) |
|
$ |
(75,112 |
) |
(1) |
Fair value changes include gains and losses related to quarterly fair value adjustments of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities, and indemnity-related holdback liabilities. |
(2) |
Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions of during the three and six months ended June 30, 2025. |
Loss from Operations |
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Loss from operations |
|
$ |
(61,774 |
) |
|
$ |
(533,492 |
) |
|
$ |
(130,463 |
) |
|
$ |
(586,766 |
) |
Stock-based compensation expense |
|
|
22,455 |
|
|
|
488,313 |
|
|
|
45,429 |
|
|
|
488,313 |
|
Employer payroll tax related to stock-based compensation |
|
|
1,873 |
|
|
|
4,762 |
|
|
|
7,126 |
|
|
|
4,762 |
|
Acquisition related expenses(1) |
|
|
1,992 |
|
|
|
— |
|
|
|
5,521 |
|
|
|
— |
|
| Franchise taxes related to IPO | 1,647 |
— |
1,647 |
— |
||||||||||||
Amortization of intangibles due to acquisition |
|
|
16,771 |
|
|
|
— |
|
|
|
27,927 |
|
|
|
— |
|
Non-GAAP loss from operations |
|
$ |
(17,036 |
) |
|
$ |
(40,417 |
) |
|
$ |
(42,813 |
) |
|
$ |
(93,691 |
) |
(1) |
Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and six months ended June 30, 2025. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250808058593/en/
Tempus Communications
Erin Carron
media@tempus.com
Tempus Investor Relations
Elizabeth Krutoholow
Elizabeth.krutoholow@tempus.com
Source: Tempus AI, Inc.
